...
首页> 外文期刊>Nanotechnology >Increasing the accumulation of aptamer AS1411 and verapamil conjugated silver nanoparticles in tumor cells to enhance the radiosensitivity of glioma
【24h】

Increasing the accumulation of aptamer AS1411 and verapamil conjugated silver nanoparticles in tumor cells to enhance the radiosensitivity of glioma

机译:增加适体AS1411和维拉帕米缀合的银纳米粒子在肿瘤细胞中的积累,以增强胶质瘤的放射敏感性

获取原文
获取原文并翻译 | 示例
           

摘要

Radioresistance significantly decreases the efficacy of radiotherapy, which can ultimately lead to tumor recurrence and metastasis. As a novel type of nano-radiosensitizer, silver nanoparticles (AgNPs) have shown promising radiosensitizing properties in the radiotherapy of glioma, but their ability to efficiently enter and accumulate in tumor cells needs to be improved. In the current study, AS1411 and verapamil (VRP) conjugated bovine serum albumin (BSA) coated AgNPs (AgNPs@BSA-AS-VRP) were synthesized and characterized. Dark-field imaging and inductively coupled plasma mass spectrometry were applied to investigate the accumulation of AgNPs@BSA-AS and AgNPs@BSA-AS-VRP mixed in different ratios in U251 glioma cells. To assess the influences of 19:1 mixed AgNPs@BSA-AS and AgNPs@BSA-AS-VRP on the P-glycoprotein (P-gp) efflux activity, rhodamine 123 accumulation assay was carried out. Colony formation assay and tumor-bearing nude mice model were employed to examine the radiosensitizing potential of 19:1 mixed AgNPs@BSA-AS and AgNPs@BSA-AS-VRP. Thioredoxin Reductase (TrxR) Assay Kit was used to detect the TrxR activity in cells treated with different functionally modified AgNPs. Characterization results revealed that AgNPs@BSA-AS-VRP were successfully constructed. When AgNPs@BSA-AS and AgNPs@BSA-AS-VRP were mixed in a ratio of 19:1, the amount of intracellular nanoparticles increased greatly through AS1411-mediated active targeting and inhibition of P-gp activity. In vitro and in vivo experiments clearly showed that the radiosensitization efficacy of 19:1 mixed AgNPs@BSA-AS and AgNPs@BSA-AS-VRP was much stronger than that of AgNPs@BSA and AgNPs@BSA-AS. It was also found that 19:1 mixed AgNPs@BSA-AS and AgNPs@BSA-AS-VRP significantly inhibited intracellular TrxR activity. These results indicate that 19:1 mixed AgNPs@BSA-AS and AgNPs@BSA-AS-VRP can effectively accumulate in tumor cells and have great potential as high-efficiency nano-radiosensitizers in the radiotherapy of glioma.
机译:放射抵抗会显著降低放疗的疗效,最终导致肿瘤复发和转移。作为一种新型的纳米放射增敏剂,银纳米颗粒(AgNPs)在胶质瘤的放射治疗中显示出良好的放射增敏特性,但其有效进入肿瘤细胞并在肿瘤细胞中聚集的能力有待提高。在目前的研究中,AS1411和维拉帕米(VRP)结合牛血清白蛋白(BSA)包被AgNPs(AgNPs@BSA-合成并表征了AS-VRP。采用暗场成像和电感耦合等离子体质谱法研究药物的积累AgNPs@BSA-以及AgNPs@BSA-AS-VRP在U251胶质瘤细胞中以不同比例混合。评估19:1混合AgNPs@BSA-以及AgNPs@BSA-在P-糖蛋白(P-gp)外排活性上,进行罗丹明123累积试验。采用集落形成实验和荷瘤裸鼠模型检测19:1混合液的放射增敏作用AgNPs@BSA-以及AgNPs@BSA-AS-VRP。硫氧还蛋白还原酶(TrxR)检测试剂盒用于检测经不同功能修饰的AgNP处理的细胞中的TrxR活性。表征结果表明AgNPs@BSA-AS-VRP已成功构建。什么时候AgNPs@BSA-以及AgNPs@BSA-当以19:1的比例混合P-VRP时,通过AS1411介导的主动靶向和抑制P-gp活性,细胞内纳米粒的数量显著增加。体外和体内实验清楚地表明,19:1的放射增敏效果是混合的AgNPs@BSA-以及AgNPs@BSA-AS-VRP比AgNPs@BSA和AgNPs@BSA-作为。还发现19:1混合AgNPs@BSA-以及AgNPs@BSA-AS-VRP显著抑制细胞内TrxR活性。这些结果表明,19:1的比例是混合的AgNPs@BSA-以及AgNPs@BSA-AS-VRP能有效地在肿瘤细胞内蓄积,在胶质瘤放射治疗中作为高效纳米放射增敏剂具有巨大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号